Inhalation Sciences’ 2019 product sales show significant growth

(Stockholm Jan’ 21, 2020) Inhalation Sciences’ preliminary revenue figures for 2019 show a record product sales revenue.

“The preliminary total revenue figure for 2019, consisting of product sales, Contract Research (CRO), training and services is 8.8 MSEK – that is a Year on Year growth of almost 62% compared to the same period in 2018 (5.4 MSEK)” says Manoush Masarrat, CEO of Inhalation Sciences AB.

The revenue for ISAB’s product sales amounts to 7 MSEK. “This is by far an all-time high for the company” Masarrat says “and we aim to continue these record revenues in 2020”.

The full 2019 Year-end Report will be published on February 20, as earlier communicated.

För mer information om detta pressmeddelande, vänligen kontakta:
Manoush Masarrat, VD
E-post: Manoush.masarrat@inhalation.se
Telefon: +46 (0)73 628 9153

About Inhalations Sciences Sweden AB (publ)

Inhalation Sciences Sweden AB (publ) develops and commercializes world-leading instruments for research into inhalation. The company’s patented lab instrument, PreciseInhale®, enables researchers to characterize, with high precision, how aerosols and small particles impact our lungs, and so our health, when we inhale them.

The information above was provided according to European Market Abuse regulations (MAR) through the agency of the contact person above, for publication on January 21, 2020.

Tags: